NS3 protease inhibitors for treatment of chronic hepatitis C: Efficacy and safety |
| |
| Authors: | Igor Bakulin Victor Pasechnikov Anna Varlamicheva Irina Sannikova |
| |
| Affiliation: | Igor Bakulin, Anna Varlamicheva, Central Scientific Research Institute of Gastroenterology of Moscow Clinical Scientific Center, 111123 Moscow, RussiaVictor Pasechnikov, Irina Sannikova, Stavropol State Medical University, 355020 Stavropol, Russia |
| |
| Abstract: | A new treatment paradigm for hepatitis C is that the treatment must include an existing direct-acting antiviral agent, namely, a protease inhibitor(PI) combined with PEGylated interferon-a and ribavirin. The currently mar-keted PIs and PIs in clinical trials have different mecha-nisms of action. The development of new PIs aims for an improved safety profile and higher effectiveness. This article reviews NS3/4A protease inhibitors, focusing on major criteria such as their effectiveness and safety. Specific attention is paid to dosing regimens and adverse event profiles of PIs administered in clinical settings. |
| |
| Keywords: | Protease inhibitor PEGylated interferon-a Ribavirin Antiviral treatment Adverse event Re-sponse-guided therapy Hepatitis C virus |
| 本文献已被 CNKI 等数据库收录！ |
| 点击此处可从《World journal of hepatology》浏览原始摘要信息 |
|
